Norwegian version of this page

K.G. Jebsen Coeliac Disease Research Centre

The primary objective of our centre is to translate recent huge advances in the basic understanding of the pathogenesis of coeliac disease to the clinic – to improve disease diagnostics, to implement novel treatments and to identify new therapeutic targets for this common disease.

The secondary objective is to become a clinical research site at the international forefront which will provide optimal patient care and which will be a unique training site for basic scientists and clinicians.


  • knuteal Transglutaminase 2 inhibitor shows great promise in clinical trial Sep. 29, 2021 10:44 AM

    Transglutaminase 2 (TG2) activity is essential to induce a pathogenic immune response towards gluten in coeliac disease. In a Phase 2 clinical trial, a daily dose of an irreversible TG2-inhibitor prevented gluten-induced mucosal destruction in coeliac patients that consumed gluten daily for 6 weeks. These findings represents a milestone in the search for treatment options for patients with coeliac disease.

  • Is regular gluten free diet sufficient to curb all anti-gluten immunity? Feb. 17, 2021 10:52 PM

    Proteomics analysis of intestinal tissue biopsies finds that some patients with celiac disease considered to be well treated by regular gluten free diet have ongoing low-level inflammation in the intestine suggestive of ongoing low-level anti-gluten immunity. These patients developed strong intestinal response following 14 -day gluten challenge. We are now investigating whether some patients may still have activated gluten-specific T-cells despite long-term gluten free diet.


Oct. 19, 2021 2:30 PM - 3:30 PM , A2.2068C/D
Oct. 20, 2021 4:00 PM - 5:00 PM , Virtual Seminar
Dec. 15, 2021 4:00 PM - 5:00 PM , Virtual Seminar
Page visits: 763